HuMax-CD4 in Non-Cutaneous T-Cell Lymphoma

An Open-Label Therapeutic Exploratory Clinical Trial of HuMax-CD4, a Fully Human Monoclonal Anti-CD4 Antibody, in Patients With Refractory or Relapsed Non-Cutaneous CD4+ T-Cell Lymphoma

Status

Completed

Phases

Phase 2Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00877656

Enrollment

Registered

2009-04-08

Start date

2005-08-31

Completion date

2008-12-31

Last updated

2024-03-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

T Cell Lymphoma

Brief summary

The purpose of this study is to assess the safety and efficacy of treatment of non-cutaneous T-cell lymphoma with treatment with CD4.

Detailed description

The study is closed and all subjects have completed treatment. The study is to evaluate the safety and efficacy of Humax CD4 with CHO vs CHO alone in subjects with non-cutaneous T cell lymphoma. The primary efficacy will be evaluated by time to relapse.

Interventions

BIOLOGICALHuMax-CD4

Active treatment

Study design

Allocation

RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Diagnostic biopsy of non cutaneous T Cell lymphoma with positive phenotype * Relapsed or refractory to minimum of one course of chemotherapy * Study is closed to enrollment.

Design outcomes

Primary

Measure	Time frame
Efficacy as measured by survival and time to disease progression	12 months

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026